Lorlatinib and the Enigma of Autoantibody-Negative Diabetes

Patients on lorlatinib may develop diabetes with unusual characteristics, including the absence of typical autoantibodies. This presents a diagnostic challenge, requiring clinicians to consider drug-induced etiologies even when initial immunological markers are negative.

JC Virus Reactivation as a Diagnostic Clue in DOCK8 Deficiency

Progressive multifocal leukoencephalopathy (PML) in young adults should prompt investigation for underlying immunodeficiencies, particularly DOCK8 deficiency. Early diagnosis allows for targeted management and potentially improved outcomes in these rare cases.

Does Vitamin D Improve Outcomes in Orthopedic Trauma?

For patients with orthopedic trauma, the question remains whether Vitamin D supplementation truly accelerates fracture healing or reduces infection risk. Existing evidence is plagued by heterogeneity and methodological weaknesses, making definitive recommendations premature.

A Systemic Approach to Atopic Dermatitis Treatment Selection

Systemic therapies for atopic dermatitis require careful patient selection and monitoring to maximize benefit and minimize risk. This case highlights the importance of considering disease severity, patient comorbidities, and prior treatment responses when choosing advanced therapies like biologics or small molecule inhibitors.

Lorlatinib and Diabetic Ketoacidosis An Emerging Class Effect?

Patients on lorlatinib should be monitored for hyperglycemia, regardless of autoantibody status. This case raises concerns about potential metabolic toxicities of ALK inhibitors beyond what is currently recognized.